A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
- Registration Number
- NCT01565291
- Lead Sponsor
- Avid Radiopharmaceuticals
- Brief Summary
A preliminary study to test how florbetapir F 18 (18F-AV-45) acts in the brains and bodies of healthy elderly people and patients with Alzheimer's Disease (AD) by using a positron emission tomography (PET) scanner.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Subjects With AD florbetapir F 18 Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24) Healthy Elderly Subjects florbetapir F 18 Cognitively normal with MMSE of 29 or higher; age 50 years or older
- Primary Outcome Measures
Name Time Method Mean Cortical to Cerebellum SUVR 50-60 min after injection Standardized Uptake Value ratio (SUVR) is the ratio of tracer uptake in predefined cortical regions, relative to uptake in the cerebellum gray matter. Total scan length was 200 min.
- Secondary Outcome Measures
Name Time Method Precuneus to Cerebellum SUVR 50-60 min after injection Ratio of uptake in the precuneus to uptake in the cerebellum.
Trial Locations
- Locations (1)
Research Site
🇺🇸Long Branch, New Jersey, United States